Use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12280026-B2
Publication Date
2025-04-22
Expiration Date
Abstract
Iguratimod, Repirinast, Lobenzarit, Actarit, Ifenprodil, Bemithyl, Bromantane, Emoxypine, Udenafil, and/or Istradefylline are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject.
Core Innovation
The disclosed invention relates to a method for the treatment or prophylaxis of renal fibrosis or kidney disease in a subject. The method comprises administering a therapeutically effective amount of Repirinast to the subject, and the disclosure also addresses chronic kidney disease as part of kidney disease progression and the need for improved treatment approaches.
The document provides disease background describing chronic kidney disease progression and the lack of established cures. It evaluates renal fibrosis and kidney disease effects using a UUO murine renal fibrosis model, where various test agents are administered orally and compared with a positive control that includes Telmisartan.
The disclosure reports evaluation endpoints including body weight, renal function (BUN/creatinine), kidney weight disparity, and Sirius Red histology scores. The results described include significant reductions in BUN and/or renal fibrosis versus vehicle for several agents, with emphasis on Repirinast and Bromantane in one study and Bemithyl/Repirinast/Bromantane in another study.
Claims Coverage
The partial content provides coverage for one independent claim and dependent claim refinements. Across the independent claim and its dependents, the inventive features are centered on administering Repirinast for treating or preventing renal fibrosis or kidney disease, optionally combined with Telmisartan at defined amounts.
Administering Repirinast for renal fibrosis or kidney disease
A method for the treatment or prophylaxis of renal fibrosis or kidney disease in a subject comprising administering a therapeutically effective amount of Repirinast to the subject.
Administering a defined Repirinast amount
The method further includes administering Repirinast in an amount between 0.5 and 20 mg per kg of the subject.
Administering about 2.5 mg per kg Repirinast
The method uses Repirinast at an amount of about 2.5 mg per kg of the subject.
Combination with Telmisartan
The method further includes administering a therapeutically effective amount of Telmisartan to the subject.
Administering defined Telmisartan amounts in combination
The method is carried out using Telmisartan in an amount of 0.1 to 5 mg per kg of the subject.
Administering about 0.25 mg per kg Telmisartan
The method further specifies that the amount of Telmisartan administered to the subject is about 0.25 mg per kg.
Overall, the claim coverage centers on treatment or prophylaxis of renal fibrosis or kidney disease by administering Repirinast, with dependent refinements specifying Repirinast amounts and optional combination therapy that adds Telmisartan with defined Telmisartan dosing.
Stated Advantages
Reduces BUN and/or renal fibrosis versus vehicle in the UUO murine renal fibrosis model.
Several agents, particularly Repirinast and Bromantane, and Bemithyl/Repirinast/Bromantane in another study, significantly improve renal fibrosis and/or BUN outcomes versus vehicle.
Documented Applications
Treatment or prophylaxis of renal fibrosis or kidney disease in a subject, including chronic kidney disease progression context.
Evaluation in a UUO murine renal fibrosis model using oral administration and assessment of renal function (BUN/creatinine) and Sirius Red histology scores.
Interested in licensing this patent?